Alec Stranahan
Stock Analyst at B of A Securities
(0.50)
# 3,946
Out of 4,944 analysts
31
Total ratings
28.57%
Success rate
-30.51%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alec Stranahan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVAX Novavax | Maintains: Neutral | $10 → $9 | $8.85 | +1.69% | 4 | Jul 22, 2025 | |
| KRYS Krystal Biotech | Maintains: Buy | $193 → $192 | $149.36 | +28.55% | 4 | Jul 22, 2025 | |
| BEAM Beam Therapeutics | Upgrades: Buy | $42 | $17.52 | +139.73% | 1 | Mar 28, 2025 | |
| YMAB Y-mAbs Therapeutics | Maintains: Neutral | $14 → $12 | $8.51 | +41.01% | 5 | Mar 5, 2025 | |
| CADL Candel Therapeutics | Initiates: Buy | $15 | $6.40 | +134.38% | 1 | Feb 7, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $28 → $25 | $6.21 | +302.58% | 4 | Jan 7, 2025 | |
| CRBU Caribou Biosciences | Maintains: Buy | $13 → $11 | $1.95 | +464.10% | 1 | Jan 7, 2025 | |
| ERAS Erasca | Upgrades: Buy | $5 | $1.63 | +207.69% | 2 | Jan 7, 2025 | |
| CATX Perspective Therapeutics | Downgrades: Neutral | $24 → $6 | $3.81 | +57.48% | 2 | Nov 25, 2024 | |
| EDIT Editas Medicine | Upgrades: Buy | $13 → $15 | $3.08 | +387.01% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $55 | $36.07 | +52.48% | 3 | Jul 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $7.72 | +444.04% | 1 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $5 → $6 | $27.87 | -78.47% | 2 | Dec 29, 2022 |
Novavax
Jul 22, 2025
Maintains: Neutral
Price Target: $10 → $9
Current: $8.85
Upside: +1.69%
Krystal Biotech
Jul 22, 2025
Maintains: Buy
Price Target: $193 → $192
Current: $149.36
Upside: +28.55%
Beam Therapeutics
Mar 28, 2025
Upgrades: Buy
Price Target: $42
Current: $17.52
Upside: +139.73%
Y-mAbs Therapeutics
Mar 5, 2025
Maintains: Neutral
Price Target: $14 → $12
Current: $8.51
Upside: +41.01%
Candel Therapeutics
Feb 7, 2025
Initiates: Buy
Price Target: $15
Current: $6.40
Upside: +134.38%
Day One Biopharmaceuticals
Jan 7, 2025
Maintains: Buy
Price Target: $28 → $25
Current: $6.21
Upside: +302.58%
Caribou Biosciences
Jan 7, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $1.95
Upside: +464.10%
Erasca
Jan 7, 2025
Upgrades: Buy
Price Target: $5
Current: $1.63
Upside: +207.69%
Perspective Therapeutics
Nov 25, 2024
Downgrades: Neutral
Price Target: $24 → $6
Current: $3.81
Upside: +57.48%
Editas Medicine
Aug 8, 2024
Upgrades: Buy
Price Target: $13 → $15
Current: $3.08
Upside: +387.01%
Jul 16, 2024
Maintains: Buy
Price Target: $48 → $55
Current: $36.07
Upside: +52.48%
May 19, 2023
Initiates: Buy
Price Target: $42
Current: $7.72
Upside: +444.04%
Dec 29, 2022
Maintains: Underperform
Price Target: $5 → $6
Current: $27.87
Upside: -78.47%